Current status of engineered T-cell therapy for synovial sarcoma. (September 2016)

• Record Type: Journal Article
• Authors: Dallos, Matthew; Tap, William D; D'Angelo, Sandra P
• Is Part Of: Immunotherapy. Volume 8:Number 9(2016:Sep.)
• Page Start: 1073
• Page End: 1080
• Publication Date: 2016-09
• Subjects: adoptive T-cell therapy -- chimeric antigen receptor -- engineered T cell -- NY-ESO-1 -- synovial sarcoma -- tumor-infiltrating lymphocytes; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2016-0026
• Languages: English
• ISSNs: 1750-743X

Abstract

Synovial sarcoma is a rare soft tissue sarcoma characterized by a t(X;18) translocation, which results in a SYT–SSX gene fusion. In the metastatic setting, chemotherapy has limited, durable efficacy prompting the necessity for new therapeutic modalities. One emerging new strategy involves T-cell-directed therapy such as tumor-infiltrating lymphocytes or the development of T cells that are genetically engineered to express a T-cell receptor against a cancer testis antigen. Of these approaches, engineered T cells that recognize NY-ESO-1 are the furthest along in development. Completed and on-going clinical trials have shown promise and there are efforts to continue to optimize the current approach.